We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

30 Jan 2020 17:00

RNS Number : 4897B
Byotrol PLC
30 January 2020
 

 

 

Byotrol plc

("Byotrol", the "Company" or the "Group")

 

Director/PDMR Shareholding

 

 

Byotrol Plc (AIM:BYOT), the anti-microbial technology company, announces that on 30 January 2020, John Langlands, Non-Executive Chairman of the Company, and Nic Hellyer, Chief Financial Officer of the Company, purchased 1,000,000 and 500,000 ordinary shares of 0.25p each ("Ordinary Shares") respectively at prices between 1.79 and 1.83 pence per Ordinary Share, respectively (the "Purchases").

Following the Purchases, Mr. Langlands has an interest in 9,000,000 Ordinary Shares representing approximately 2.04 per cent. of the total voting rights of the Company and Nic Hellyer has an interest in 500,000 Ordinary Shares representing approximately 0.11 per cent. of the total voting rights of the Company.

 

 

 

Enquiries:

David Traynor - Chief Executive, Byotrol plc 01925 742 000

David Paton - Investor Relations 07714 190 474

finnCap Ltd 020 7110 0500(NominateAdviser & Broker)

Geoff Nash/Teddy Whiley Corporate Finance

Richard Chambers - Corporate Broking

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

 

Noteto Editors: 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

Our patented suite of technologies delivers powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.

Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

For more information, please go to www.byotrol.co.uk

 

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Langlands

2.

Reason for the Notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification/Amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

213800AJMTSTIPA59A34

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of 0.25p each

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Volume - 250,000

Price - 1.7975 pence

Volume - 500,000

Price - 1.83 pence

Volume - 250,000

Price - 1.79 pence

d)

Aggregated information:

Volume - 1,000,000

Aggregated price - 1.81 pence

e)

Date of the transaction

30 January 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Nic Hellyer

2.

Reason for the Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

213800AJMTSTIPA59A34

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of 0.25p each

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Volume - 278,164

Price - 1.7975 pence

Volume - 221,836

Price - 1.799 pence

d)

Aggregated information:

Volume - 500,000

Aggregated Price - 1.798 pence

e)

Date of the transaction

30 January 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDZGFMVGRGGZM
Date   Source Headline
5th Sep 20077:01 amRNSDirector/PDMR Shareholding
4th Sep 20077:00 amRNSDirectorate Change
31st Aug 200710:07 amRNSTotal Voting Rights
16th Aug 20078:41 amRNSAIM RULE 26 INFORMATION
6th Aug 20072:49 pmRNSAdditional Listing
1st Aug 20078:21 amRNSTotal Voting Rights
1st Aug 20077:01 amRNSDirector/PDMR Shareholding
30th Jul 20071:04 pmRNSAGM Statement
30th Jul 20077:01 amRNSJoint Venture
20th Jun 20077:01 amRNSAnnual Report and Accounts
8th Jun 20077:00 amRNSAdditional Listing
4th Jun 20077:00 amRNSNEW GLOBAL CONTRACT
4th May 20077:01 amBUSBYOTROL plc • HEALTHCARE PRODUCT LAUNCH
18th Apr 20077:45 amRNSTrading Statement
30th Mar 20079:24 amRNSTotal Voting Rights
22nd Mar 20072:47 pmRNSHolding(s) in Company
19th Mar 20079:56 amRNSHolding(s) in Company
19th Mar 20079:52 amRNSHolding(s) in Company
19th Mar 20079:51 amRNSHolding(s) in Company
19th Mar 20079:49 amRNSHolding(s) in Company
13th Mar 20073:28 pmRNSAdditional Listing
28th Feb 20071:04 pmRNSTotal Voting Rights
23rd Feb 20077:01 amRNSAdditional Listing
21st Feb 20077:01 amRNSDirector/PDMR Shareholding
8th Feb 20073:54 pmRNSAdditional Listing
5th Feb 20072:52 pmRNSHolding(s) in Company
19th Jan 20072:30 pmRNSTotal Voting Rights
12th Jan 20073:07 pmRNSIssue of Equity
14th Dec 20065:00 pmRNSTotal Voting Rights
11th Dec 20067:00 amRNSInterim Results
27th Nov 20069:32 amRNSBoard Appointment
14th Nov 20067:03 amRNSSynergy Healthcare Agreement
1st Nov 20067:01 amRNSIssue of Equity
26th Oct 20061:12 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 20061:02 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 200612:28 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 200610:24 amRNSDistribution Agreements
16th Oct 20067:01 amBUSByotrol Plc: Result of Byotrol Use in Hospital
18th Sep 200610:56 amBUSREPEAT: Byotrol Plc: Chinese Patent Granted and Customer Orders Shipped
18th Sep 200610:30 amBUSByotrol Plc: Chinese Patent Granted and Customer Orders Shipped
11th Sep 20067:01 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.